Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Roche identifies new MAGL inhibitors

April 6, 2021

Initial clinical data from phase I/II SWORD-1 study of TPX-0046

April 6, 2021

Safety cohort data from phase II study of prexigebersen plus frontline therapies for AML

April 6, 2021

Yingli reports phase II topline data on linperlisib in relapsed or refractory follicular lymphoma

April 1, 2021

China's NMPA approves Ayvakit for GIST with PDGFRA exon 18 mutation

April 1, 2021

Qinlock approved in China for advanced GIST

April 1, 2021

COMMD1 as therapeutic target and diagnostic biomarker in NSCLC

April 1, 2021

Sichuan Kelun-Biotech Biopharmaceutical patents nuclear receptor ROR-gamma agonists

April 1, 2021

New Nur77 receptor ligands disclosed by Ixmedicine

April 1, 2021

IMPACT Therapeutics identifies new ATM kinase inhibitors

April 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...